Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of HEC30654AcOH in Healthy Subjects
NCT03655873Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing HEC30654AcOH capsule with Placebo capsule (2 arms). Primary endpoints: Adverse events of the single ascending-dose and Adverse events of the multiple ascending-dose. Started Nov 2018; status: completed.
02
Drugs
HEC30654
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03655873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03655873.